Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and
low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian
cancer.